FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095698687> ?p ?o ?g. }

• W2095698687 endingPage "5178" @default.
• W2095698687 startingPage "5170" @default.
• W2095698687 abstract "Abstract Purpose: p53 as a prognostic and predictive factor in early-stage breast cancer has had mixed results. We studied p53 protein expression, by immunohistochemistry, in a randomized clinical trial of stage II patients treated with adjuvant doxorubicin and cyclophosphamide with or without paclitaxel [Cancer and Leukemia Group B (CALGB) 9344, INT0148]. Patients and Methods: Epithelial p53 expression was evaluated using two immunohistochemical antibodies (DO7 and 1801) in formalin-fixed, paraffin-embedded tissue from patients with node-positive breast cancer who were randomized to four cycles of cyclophosphamide and one of three doses of doxorubicin (60, 75, or 90 mg/m2; AC) and to receive four subsequent cycles of paclitaxel (T) or not. Prognostic and predictive value of p53 protein expression was assessed, independent of treatment assignment, for escalating doses of doxorubicin or addition of T with endpoints of relapse-free (RFS) and overall survival (OS). Results: Of 3,121 patients, 1,887 patient specimens treated on C9344 were obtained, passed quality control, and evaluated for p53 expression. Expression was 23% and 27% for mAbs 1801 and D07, respectively, with 92% concordance. In univariate analysis, p53 positivity was associated with worse OS with either antibody, but only p53 staining with monoclonal antibody 1801 had significantly worse RFS. In multivariate analysis, p53 was not predictive of RFS or OS from either doxorubicin dose escalation or addition of paclitaxel regardless of the antibody. Conclusion: Nuclear staining of p53 by immunohistochemistry is associated with worse prognosis in node-positive patients treated with adjuvant doxorubicin-based chemotherapy but is not a useful predictor of benefit from doxorubicin dose escalation or the addition of paclitaxel. Clin Cancer Res; 17(15); 5170–8. ©2011 AACR." @default.
• W2095698687 created "2016-06-24" @default.
• W2095698687 creator A5007925654 @default.
• W2095698687 creator A5013400628 @default.
• W2095698687 creator A5019925910 @default.
• W2095698687 creator A5030358067 @default.
• W2095698687 creator A5034228539 @default.
• W2095698687 creator A5036752365 @default.
• W2095698687 creator A5039225060 @default.
• W2095698687 creator A5047713528 @default.
• W2095698687 creator A5049331116 @default.
• W2095698687 creator A5051712278 @default.
• W2095698687 creator A5054042253 @default.
• W2095698687 creator A5057135409 @default.
• W2095698687 creator A5062031844 @default.
• W2095698687 creator A5069748055 @default.
• W2095698687 creator A5070245248 @default.
• W2095698687 creator A5073571977 @default.
• W2095698687 creator A5083904553 @default.
• W2095698687 date "2011-07-31" @default.
• W2095698687 modified "2023-09-26" @default.
• W2095698687 title "p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905)" @default.
• W2095698687 cites W1518116733 @default.
• W2095698687 cites W1606439671 @default.
• W2095698687 cites W1970731925 @default.
• W2095698687 cites W1975619340 @default.
• W2095698687 cites W1976052438 @default.
• W2095698687 cites W1987783969 @default.
• W2095698687 cites W2000557631 @default.
• W2095698687 cites W2012314095 @default.
• W2095698687 cites W2043630729 @default.
• W2095698687 cites W2043657056 @default.
• W2095698687 cites W2063939395 @default.
• W2095698687 cites W2065401544 @default.
• W2095698687 cites W2075845830 @default.
• W2095698687 cites W2079669150 @default.
• W2095698687 cites W2081894694 @default.
• W2095698687 cites W2084302685 @default.
• W2095698687 cites W2091205535 @default.
• W2095698687 cites W2097482525 @default.
• W2095698687 cites W2111703821 @default.
• W2095698687 cites W2113499049 @default.
• W2095698687 cites W2117305280 @default.
• W2095698687 cites W2121331514 @default.
• W2095698687 cites W2129936913 @default.
• W2095698687 cites W2135372807 @default.
• W2095698687 cites W2135800076 @default.
• W2095698687 cites W2136802843 @default.
• W2095698687 cites W2140420106 @default.
• W2095698687 cites W2151191704 @default.
• W2095698687 cites W2151726995 @default.
• W2095698687 cites W2162975775 @default.
• W2095698687 cites W2163814095 @default.
• W2095698687 cites W2163853500 @default.
• W2095698687 cites W2222470382 @default.
• W2095698687 doi "https://doi.org/10.1158/1078-0432.ccr-11-0484" @default.
• W2095698687 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3149770" @default.
• W2095698687 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21693655" @default.
• W2095698687 hasPublicationYear "2011" @default.
• W2095698687 type Work @default.
• W2095698687 sameAs 2095698687 @default.
• W2095698687 citedByCount "30" @default.
• W2095698687 countsByYear W20956986872012 @default.
• W2095698687 countsByYear W20956986872013 @default.
• W2095698687 countsByYear W20956986872014 @default.
• W2095698687 countsByYear W20956986872015 @default.
• W2095698687 countsByYear W20956986872016 @default.
• W2095698687 countsByYear W20956986872017 @default.
• W2095698687 countsByYear W20956986872018 @default.
• W2095698687 countsByYear W20956986872019 @default.
• W2095698687 countsByYear W20956986872020 @default.
• W2095698687 countsByYear W20956986872021 @default.
• W2095698687 countsByYear W20956986872023 @default.
• W2095698687 crossrefType "journal-article" @default.
• W2095698687 hasAuthorship W2095698687A5007925654 @default.
• W2095698687 hasAuthorship W2095698687A5013400628 @default.
• W2095698687 hasAuthorship W2095698687A5019925910 @default.
• W2095698687 hasAuthorship W2095698687A5030358067 @default.
• W2095698687 hasAuthorship W2095698687A5034228539 @default.
• W2095698687 hasAuthorship W2095698687A5036752365 @default.
• W2095698687 hasAuthorship W2095698687A5039225060 @default.
• W2095698687 hasAuthorship W2095698687A5047713528 @default.
• W2095698687 hasAuthorship W2095698687A5049331116 @default.
• W2095698687 hasAuthorship W2095698687A5051712278 @default.
• W2095698687 hasAuthorship W2095698687A5054042253 @default.
• W2095698687 hasAuthorship W2095698687A5057135409 @default.
• W2095698687 hasAuthorship W2095698687A5062031844 @default.
• W2095698687 hasAuthorship W2095698687A5069748055 @default.
• W2095698687 hasAuthorship W2095698687A5070245248 @default.
• W2095698687 hasAuthorship W2095698687A5073571977 @default.
• W2095698687 hasAuthorship W2095698687A5083904553 @default.
• W2095698687 hasBestOaLocation W20956986871 @default.
• W2095698687 hasConcept C121608353 @default.
• W2095698687 hasConcept C126322002 @default.
• W2095698687 hasConcept C142724271 @default.
• W2095698687 hasConcept C143998085 @default.
• W2095698687 hasConcept C204232928 @default.
• W2095698687 hasConcept C2776694085 @default.

• next